Vivoryon Therapeutics N.V. (0R3M.L)

EUR 1.66

(-2.24%)

Operating Income Summary of Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V.'s latest annual operating income in 2023 was -28.83 Million EUR , down -0.69% from previous year.
Vivoryon Therapeutics N.V.'s latest quarterly operating income in 2024 Q2 was -13.8 Million EUR , down 0.0% from previous quarter.
Vivoryon Therapeutics N.V. reported an annual operating income of -29.13 Million EUR in 2022, down -127.49% from previous year.
Vivoryon Therapeutics N.V. reported an annual operating income of -12.8 Million EUR in 2021, up 20.05% from previous year.
Vivoryon Therapeutics N.V. reported a quarterly operating income of -10.69 Million EUR for 2023 Q2, down 0.0% from previous quarter.
Vivoryon Therapeutics N.V. reported a quarterly operating income of -29.33 Million EUR for 2023 FY, down -0.69% from previous quarter.

Annual Operating Income Chart of Vivoryon Therapeutics N.V. (2023 - 2011)

Historical Annual Operating Income of Vivoryon Therapeutics N.V. (2023 - 2011)

Year	Operating Income	Operating Income Growth
2023	-28.83 Million EUR	-0.69%
2022	-29.13 Million EUR	-127.49%
2021	-12.8 Million EUR	20.05%
2020	-16.01 Million EUR	-106.03%
2019	-7.77 Million EUR	-0.61%
2018	-7.72 Million EUR	22.46%
2017	-9.96 Million EUR	28.1%
2016	-13.86 Million EUR	-3.15%
2015	-13.43 Million EUR	-19.26%
2014	-11.26 Million EUR	-16.74%
2013	-9.65 Million EUR	8.59%
2012	-10.55 Million EUR	26.01%
2011	-14.26 Million EUR	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	-13.8 Million EUR	0.0%
2023 Q2	-10.69 Million EUR	0.0%
2023 FY	-29.33 Million EUR	-0.69%
2023 Q4	-17.54 Million EUR	0.0%
2022 FY	-29.13 Million EUR	-127.49%
2022 Q2	-13.37 Million EUR	0.0%
2022 Q4	-15.75 Million EUR	0.0%
2021 Q4	-1.01 Million EUR	0.0%
2021 Q2	-11.79 Million EUR	0.0%
2021 FY	-12.8 Million EUR	20.05%
2020 FY	-16.01 Million EUR	-106.03%
2020 Q4	-8.49 Million EUR	0.0%
2020 Q2	-7.51 Million EUR	0.0%
2019 Q4	-4.68 Million EUR	0.0%
2019 FY	-7.77 Million EUR	-0.61%
2019 Q2	-3.08 Million EUR	0.0%
2018 Q2	-4.13 Million EUR	0.0%
2018 Q4	-3.56 Million EUR	0.0%
2018 FY	-7.72 Million EUR	22.46%
2017 Q2	-6.26 Million EUR	0.0%
2017 FY	-9.96 Million EUR	28.1%
2017 Q4	-3.69 Million EUR	0.0%
2016 FY	-13.86 Million EUR	-3.15%
2016 Q4	-7.78 Million EUR	0.0%
2016 Q2	-5.98 Million EUR	0.0%
2015 FY	-13.43 Million EUR	-19.26%
2015 Q2	-6.17 Million EUR	0.0%
2015 Q4	-7.21 Million EUR	0.0%
2014 Q2	-3.73 Million EUR	0.0%
2014 FY	-11.26 Million EUR	-16.74%
2014 Q4	-7.52 Million EUR	0.0%
2013 Q4	-4.88 Million EUR	-99.23%
2013 FY	-9.65 Million EUR	8.59%
2013 Q3	-2.45 Million EUR	48.49%
2013 Q2	-4.76 Million EUR	-94.13%
2013 Q1	-2.45 Million EUR	0.0%
2012 Q1	-4.43 Million EUR	0.0%
2012 Q3	-4.43 Million EUR	0.0%
2012 Q4	-2.45 Million EUR	44.63%
2012 FY	-10.55 Million EUR	26.01%
2012 Q2	-4.43 Million EUR	0.0%
2011 Q4	-4.43 Million EUR	-9.12%
2011 Q1	-4.06 Million EUR	0.0%
2011 Q3	-4.06 Million EUR	0.0%
2011 Q2	-4.06 Million EUR	0.0%
2011 FY	-14.26 Million EUR	0.0%
2010 Q4	-4.06 Million EUR	0.0%

Peer Operating Income Comparison of Vivoryon Therapeutics N.V.

Name	Operating Income	Operating Income Difference
Boiron SA	42.29 Million EUR	168.189%
Laboratorios Farmaceuticos Rovi, S.A.	220.25 Million EUR	113.093%
Vetoquinol SA	74.26 Million EUR	138.83%
Valneva SE	-82.08 Million EUR	64.87%
AB Science S.A.	-13.42 Million EUR	-114.737%
Nanobiotix S.A.	-26.77 Million EUR	-7.685%
PHAXIAM Therapeutics S.A.	-23.66 Million EUR	-21.881%
BioSenic S.A.	-7.04 Million EUR	-309.616%
ABIVAX Société Anonyme	-127.37 Million EUR	77.361%
Formycon AG	-369 Thousand EUR	-7714.905%